Open Access

miR‑150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B‑cell lymphoma

  • Authors:
    • Xinyuan Wang
    • Yutian Kan
    • Leiyuan Chen
    • Peng Ge
    • Tingting Ding
    • Qiongli Zhai
    • Yong Yu
    • Xiaofang Wang
    • Zhigang Zhao
    • Hongliang Yang
    • Xianming Liu
    • Lanfang Li
    • Lihua Qiu
    • Zhengzi Qian
    • Huilai Zhang
    • Yafei Wang
    • Haifeng Zhao
  • View Affiliations

  • Published online on: March 10, 2020     https://doi.org/10.3892/ol.2020.11452
  • Pages: 3487-3494
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A number of studies suggest an association between miRNAs and diffuse large B‑cell lymphoma (DLBCL). The present study aimed to investigate the prognostic value of microRNA (miR‑150) in primary gastrointestinal (PGI)‑DLBCL, by assessing the association between miR‑150 expression and clinicopathological characteristics in patients with PGI‑DLBCL. A total of 84 patients diagnosed with PGI‑DLBCL were recruited and both tumor and adjacent non‑tumor tissue samples were collected. miR‑150 expression was assessed via reverse transcription‑quantitative (RT‑q)PCR analysis. The results demonstrated that miR‑150 expression was significantly lower in PGI‑DLBCL tissues compared with adjacent non‑tumor tissues. Furthermore, receiver operating characteristic (ROC) curve analysis indicated that the optimal cut‑off value of miR‑150 for predicting survival was 8.965 with high sensitivity (79.8%) and specificity (77.1%). Patients were divided into two groups according to this cut‑off value, as follows: High (n=18) and low expression (n=66) groups. Low miR‑150 expression was significantly associated with clinical stage, International Prognostic Index (IPI), Eastern Cooperative Oncology Group status and use of rituximab. RT‑qPCR analysis demonstrated that miR‑150 expression was significantly lower in patients with high IPI scores compared with patients with low IPI scores. Downregulated miR‑150 expression was significantly associated with shorter overall survival (OS) time and progression‑free survival (PFS) time in patients with PGI‑DLBCL. Furthermore, miR‑150 level and IPI score were identified as two risk factors for OS and PFS. The diagnostic value of miR‑150 was evaluated via ROC curve analysis, with an area under the curve value of 0.882. Taken together, the results of the present study suggest that miR‑150 is a potential diagnostic marker of PGI‑DLBCL, and may also serve as a useful prognostic factor for survival outcomes in patients with PGI‑DLBCL.

Related Articles

Journal Cover

May 2020
Volume 19 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Wang, X., Kan, Y., Chen, L., Ge, P., Ding, T., Zhai, Q. ... Zhao, H. (2020). miR‑150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B‑cell lymphoma. Oncology Letters, 19, 3487-3494. https://doi.org/10.3892/ol.2020.11452
MLA
Wang, X., Kan, Y., Chen, L., Ge, P., Ding, T., Zhai, Q., Yu, Y., Wang, X., Zhao, Z., Yang, H., Liu, X., Li, L., Qiu, L., Qian, Z., Zhang, H., Wang, Y., Zhao, H."miR‑150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B‑cell lymphoma". Oncology Letters 19.5 (2020): 3487-3494.
Chicago
Wang, X., Kan, Y., Chen, L., Ge, P., Ding, T., Zhai, Q., Yu, Y., Wang, X., Zhao, Z., Yang, H., Liu, X., Li, L., Qiu, L., Qian, Z., Zhang, H., Wang, Y., Zhao, H."miR‑150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B‑cell lymphoma". Oncology Letters 19, no. 5 (2020): 3487-3494. https://doi.org/10.3892/ol.2020.11452